Q-omics provides the consensus-scored KIF26A profile across patient tissues and cancer cell-line models. KIF26A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KIF26A is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, KIF26A RNA expression shows 18,469 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUAD, and TGCT as cancer lineages where KIF26A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF26A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF26A survival associations across molecular data types. KIF26A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF26A RNA expression–survival associations across cancer types. High KIF26A expression shows unfavorable associations in ACC, BLCA, COAD, KIRP and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KIF26A RNA expression.
This table summarizes KIF26A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF26A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF26A shows lower tumor expression in LUAD, BLCA, KICH, THCA, KIRP and KIRC. The LUAD box plot shows higher KIF26A RNA expression in normal versus tumor tissue (log2 FC = −1.460, t-test p < 0.001).
This table shows molecular features associated with KIF26A in patient tissues and cancer cell lines. In patient samples, KIF26A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF26A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
